|Summary sheet: NM-2-AI|
|Chemical class||Amphetamine / Aminoindane|
|Routes of Administration|
In comparison to 2-AI, this compound has a lower potency, a longer duration and very similar effects. It has recently become easily accessible through online research chemical vendors where it is sold as a designer drug.
Very little data exists for the effects, pharmacology, and toxicity of NM-2-AI. It is highly advised to use harm reduction practices if using this substance.
NM-2-AI, or N-methyl-2-AI, is the N-methylated derivative of 2-Aminoindane and is analogous to amphetamine. It features the R3 terminal carbon of the propane chain of amphetamine bound to the benzene ring. This creates an indane, a bicycle containing a benzene ring fused to a pentane ring. The amino group 2-AI shares with amphetamine is bound to R2 of the indane group. N-methyl-2-AI contains a methyl group bound to the amino group RN (for which it is named).
Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is speculation purely based upon its structure and subjective effect similarities to other stimulants such as amphetamine, methamphetamine and 2-FMA. It is speculated that NM-2-AI most likely acts as both a dopamine and norepinephrine releasing agent. This means it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses are more likely to induce the full spectrum of effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.
- Stimulation - In terms of its effects on the physical energy levels of the user, NM-2-AI is usually considered to be energetic and stimulating in a fashion that is similar to that of amphetamine but stronger than that of modafinil or caffeine. It is similar yet distinct from the stimulation experienced on MDMA, encouraging physical activities such as dancing, socializing, running, or cleaning. The particular style of stimulation which NM-2-AI presents can be described as forced. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily bodily shakes and vibrations become present, resulting in extreme shaking of the entire body, unsteadiness of the hands, and a general lack of motor control.
- Increased heart rate
- Appetite suppression
- Temporary erectile dysfunction
- Increased perspiration
- Increased blood pressure
- Teeth grinding - This component can be considered to be less intense when compared with that of MDMA.
- The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" and occurs because of neurotransmitter depletion. Its effects commonly include:
The cognitive effects of NM-2-AI can be broken down into several components which progressively intensify proportional to dosage. The general head space of NM-2-AI is described by many as one of mental stimulation, increased focus, and euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate doses, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
The most prominent of these cognitive effects generally include:
- Focus enhancement - This component is most effective at low to moderate doses as anything higher will usually impair concentration.
- Motivation enhancement - This compound can be considered as slightly more functional than that of 2-AI and therefore more effective for performing tasks whilst under its influence.
- Euphoria - This compound can be considered as considerably less euphoric than that of 2-AI and therefore less effective for recreational purposes.
- Thought acceleration
- Analysis enhancement
- Memory enhancement
- Motivation enhancement
- Compulsive redosing
- Increased music appreciation
Toxicity and harm potential
The toxicity and long-term health effects of recreational NM-2-AI use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because NM-2-AI has very little history of human usage. Anecdotal evidence from people who have tried NM-2-AI within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
As with other stimulants, the chronic use of NM-2-AI can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of NM-2-AI develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). NM-2-AI presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of NM-2-AI all stimulants will have a reduced effect.
Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions). A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Stimulants - NM-2-AI can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
- 25x-NBOMe & 25x-NBOH - Members of the 25x family are highly stimulating and physically straining. Combinations with stimulants should be avoided due to the risk of excessive stimulation. This can result in panic attacks, thought loops, seizures, increased blood pressure, vasoconstriction, and heart failure in extreme cases.
- Alcohol - Alcohol can be dangerous to combine with stimulants due to the risk of accidental over-intoxication. Stimulants mask the sedative effects of alcohol, which is the main factor people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects of alcohol are left unopposed, which can result in blackouts and respiratory depression. If combined, one should strictly limit themselves to only drinking a certain amount of alcohol per hour.
- DXM - Combinations with DXM should be handled with extreme care due to DXM's effects on serotonin and norepinephrine reuptake. This can lead to panic attacks, hypertensive crisis, or serotonin syndrome with stimulants that increase levels of serotonin (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
- MDMA - The neurotoxic effects of MDMA may be increased when combined with other stimulants. There is also a risk of excessive heart strain.
- MXE - Combinations with MXE may dangerously elevate blood pressure and increase the risk of psychosis.
- Stimulants - NM-2-AI can be potentially dangerous in combination with other stimulants as they can increase one's heart rate and blood pressure to dangerous levels.
- Cocaine - This combination may increase strain on the heart.
- Tramadol - Tramadol lowers the seizure threshold. Combinations with stimulants may further increase this risk.
- MDMA - The neurotoxic effects of MDMA may be increased when combined with amphetamine and other stimulants.
- MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, and some antidepressants.
- Cocaine - This combination may increase strain on the heart.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
NM-2-AI is currently believed to be a grey area compound within most parts of the world. This means that it is not known to be specifically illegal within any country but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
- Germany: NM-2-AI is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- Switzerland: NM-2-AI is a controlled substance specifically named under Verzeichnis E.
- United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- "Treatment for amphetamine psychosis"
- Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
- Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi: . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 23, 2019.
- "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 23, 2019.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 23, 2019.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted